CF PHARMTECH: Li Li Bovet Acquires Shares, Long Position Rises to 18.74%
HK Disclosure
Oct 02
On September 28, 2026, Li Li Bovet's long position in CF PHARMTECH increased after Dr. LIANG Bill Wenqing, a party acting in concert with Li Li Bovet, purchased 25,100 H shares of the company on the SEHK open market at an average of HKD 7.2916 per share, involving about HKD 183,019.
Prior to the acquisition, Li Li Bovet's long position in CF PHARMTECH was 60.67 million shares, representing 18.73%; following the acquisition, the holding changed to 60.70 million shares, with the long position ratio rising to 18.74%.
This involves related parties: 苏州岭头投资管理企业（有限合伙）, 苏州沃伦企业管理中心（有限合伙）, and 岭头投资有限公司.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.